Gilead (GILD) Q1 FY26 earnings call

Gilead delivered a strong first quarter, marked by robust commercial execution across its HIV, oncology, and liver disease portfolios, leading to an upward revision of its full-year revenue guidance. The company is actively strengthening its pipeline through strategic acquisitions in ADC and cell therapy, while advancing numerous clinical programs. Despite seasonal headwinds and policy-related impacts, Gilead maintains a disciplined financial approach, aiming for continued growth and impact on patients.